SAN DIEGO, July 1, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed recruitment in the Phase IIb clinical trial (Kinect Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The final subject will randomize this week. The design of this twelve-week Phase IIb study is a randomized, parallel, double-blind, placebo-controlled trial of 120 subjects with moderate to severe tardive dyskinesia and underlying schizophrenia or schizoaffective disorder. Topline data from the placebo-controlled portion of the trial is expected in approximately ten weeks. "We are pleased with the baseline characteristics of subjects who have been randomized into this study and the conduct thus far of this clinical trial has been outstanding," said Christopher F. O'Brien, Chief Medical Officer of Neurocrine Biosciences. "Completing enrollment of this Phase IIb study is another milestone in the development of NBI-98854 and we look forward to sharing the top-line results shortly." Kinect Study Design The Kinect Study is a randomized, parallel, double-blind, placebo-controlled, Phase IIb clinical trial utilizing the capsule formulation of NBI-98854 in moderate to severe tardive dyskinesia patients with underlying schizophrenia or schizoaffective disorder. This 120 subject study is assessing two doses of once-daily NBI-98854 over a six-week placebo-controlled dosing period. Half of the randomized subjects are receiving placebo and half are receiving one of two doses of NBI-98854. The two NBI-98854 dosing groups consist of a 50mg group for six weeks and a group that will begin at 100mg for the initial two weeks then convert to 50mg for the final four weeks of the placebo-controlled dosing period. Subsequent to the placebo-controlled dosing, all subjects enter a six-week open label safety extension of 50mg of NBI-98854 administered once daily with additional Abnormal Involuntary Movement Scale (AIMS) assessments. The primary endpoint of the study is a comparison of placebo vs. active scores utilizing the AIMS at the end of week six.